Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-high-risk early breast cancer

Paluch-Shimon, S.Neven, P.Huober, J.Cicin, I.Jiang, Z.Goetz, M. P.Shimizu, C.2024-06-122024-06-1220220923-75341569-8041https://doi.org/10.1016/j.annonc.2022.03.079https://hdl.handle.net/20.500.14551/25578European-Society-for-Medical-Oncology (ESMO) Breast Cancer Congress -- MAY 03-05, 2022 -- Berlin, GERMANY[Abstract Not Available]en10.1016/j.annonc.2022.03.079info:eu-repo/semantics/openAccess[No Keywords]Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-high-risk early breast cancerConference Object33S151S151Q1WOS:000792494100065